New MS therapies reduce relapses as Albacete clinic seeks accreditation

Patients benefit from improved treatment efficacy and quality of life, reducing long-term disability costs and enabling continued workforce participation. However, high-efficacy drugs likely increase out-of-pocket costs for some patients despite improved outcomes.

Healthcare systems must allocate resources for specialized MS units and accreditation standards. Pharmaceutical pricing regulations may face pressure as high-efficacy treatments command premium costs. Public health systems should consider coverage expansion for disease-modifying therapies to prevent disability-related social costs.

Progress narrative emphasizing medical advancement and institutional achievement (clinic accreditation); uses expert authority to validate claims without counterbalance